Clinical trial
An Open-Label, Multiple-dose, Parallel Group Study to Evaluate the Pharmacokinetics of MK-6916 in Participants With Severe Renal Impairment and Moderate Renal Impairment
NCT07922174 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multiple-dose, Parallel Group Study to Evaluate the Pharmacokinetics of MK-6916 in Participants With Severe Renal Impairment and Moderate Renal Impairment
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- December 11, 2026
- Completion date
- August 8, 2027
- Enrollment
- 32 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
healthy, renal impairment
Arms
As registered; 3 arms.
-
Panel A: Severe Renal Impairment
Participants with severe renal impairment will receive multiple doses of MK-6916 on Days 1-15 and a single oral dose on Day 16 under fasting conditions.
-
Panel B: Moderate Renal Impairment
Participants with moderate renal impairment will receive multiple doses of MK-6916 on Days 1-15 and a single oral dose on Day 16 under fasting conditions.
-
Panel C: Healthy
Healthy participants will receive multiple doses of MK-6916 on Days 1-15 and a single oral dose on Day 16 under fasting conditions.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Area Under the Concentration-Time Curve from Time 0 to 12 Hours (AUC0-12) of MK-6916 on Day 16
Blood samples will be collected to determine the AUC0-12 of MK-6916.
Lead sponsor's other trials
Merck Sharp & Dohme LLC, most recent start first.
+2,160 more trials
Similar trials
Same condition (Renal Insufficiency) and phase, most recent start first.
+388 more trials See the condition page